Banner overlay


Faster Learning, Enhanced Memory & Improved Mental Performance
Benifit Image
35 Years
Synapsa has been the subject of scientific study for over three decades.
Benifit Image
689 Subjects
Synapsa’s efficacy has been established with a large, diverse study population.
Benifit Image
6 Clinical Studies
Synapsa is one of the most studied cognitive support ingredients available today.
Benifit Image
19 Potential Claims
The Synapsa Claims Dossier can help you identify compelling messaging for consumers grounded in the clinical science.

Give Them an Edge

Synapsa Natural Memory Support is a patented, standardized form of Bacopa monnieri that has been the subject of more than 35 years of clinical study. While most cognitive health supplements focus on the issue of cognitive decline – mainly in an aging population – the studies behind Synapsa focus on ‘peak cognitive performance’ outcomes that offer benefits for a much broader public. In six double-blind, placebo-controlled clinical studies, healthy adults using Synapsa showed significantly improved performance in areas such as visual processing, learning rate, working memory, information retention and mental performance in cognitively demanding environments versus a placebo regimen.

Good For
Ingredient Solutions
Cognitive and Mood Support
Healthy Aging
Stick Packs
Soft Gels


The range of potential benefits from Synapsa include faster information processing, improved learning rate, decreased forgetting rate, improved memory consolidation and better multitasking accuracy. Those are the types of benefits today’s knowledge worker needs!


Relevant Studies for the ‘Peak Performance’ Demographic

The patented, standardized Synapsa extract has been the focus of seven ‘foundational’ clinical trials and six ‘targeted’ clinical trials over the last thirty-five years. The most intriguing studies include:

Stough, 2001 showed a statistically significant improvement in speed of visual information processing, learning rate and memory consolidation in subjects 18-60 years of age consuming 300 mg/day Synapsa. A statistically significant reduction in the rate of forgetting was also observed.

Roodenrys, 2002 conducted a randomized, double-blind, placebo-controlled 12-week trial that demonstrated a significant effect of Synapsa (300mg/d) on the retention of new information by participants 40-65 years of age.

Stough, 2008 conducted a randomized double-blind, placebo-controlled 90-day study with 62 participants, ages 18-60, consuming 300 mg/day. Synapsa showed a statistically significant improvement in working memory, visual information processing (sustained attention) and accuracy in complex cognitive tasks.

Downey, 2012 studied two different doses (320 mg/640 mg) in a study on sustained cognitive performance, examining the acute (short term) effect of Synapsa in healthy adult subjects. Significantly improved performance was seen in faster information processing and improved decision-making time in a multitasking environment.

The Synapsa Claims Dossier

To support commercialization efforts for our Synapsa Natural Memory Support ingredient, PLT has developed a comprehensive claims dossier in conjunction with a third-party reviewer focused on claims support and scientific communications to provide an impartial review of the validity of the science supporting Synapsa claims.

The Synapsa Claims Dossier includes a comprehensive list of potential/proposed claims, a legal executive summary and in-depth reviews of how the claims can be supported by the data. In the case of Synapsa, these include ‘chronic’ claims – that cover long-term use of the ingredient, ‘acute’ claims that are based around short-term, experiential use of the ingredient and general claims in the area of cognitive health. The Comprehensive List of Claims in the new dossier includes in-depth reviews on supporting 19 different potential claims for consumer products that contain or feature Synapsa.

Two types of use supported by studies

Studies show support for two distinct types of benefit from Synapsa Natural Memory Support: daily, long-term use (chronic) to enhance learning and memory, and short-term use (acute) to improve mental performance in cognitively demanding environments such as test-taking. In addition, the majority of studies behind Synapsa have been conducted on healthy adult subjects between 18-65. From a market standpoint, in the United States today, more than 120 million people are considered knowledge workers who use cognitive skills as a daily part of their jobs. In addition, recent estimates of college students range upwards of 21 million. Both groups are good targets for new formulations based on Synapsa, along with any consumers looking for support for learning, memory and mental performance.

What is Synapsa?

Synapsa Natural Memory Support is a unique, standardized extract of Bacopa monnieri, with a wide range of active constituents that contribute to its therapeutic properties. Bacopa monnieri (also known as brahmi) is an herb that has been used in traditional Ayurvedic medicine for centuries.

Today’s proprietary Synapsa ingredient is based on a patented extraction process that follows an exacting farming and manufacturing process to ensure a standardized level of quality – since each step of this process can influence the final product’s complex phytochemical profile and therapeutic action. Putting farming & manufacturing controls in place across each step allows for consistency of the entire product & results in a product that can be clinically studied.




Synapsa is a trademark of Soho Flordis International Pty Ltd., exclusively licensed in the United States to PLT Health Solutions, Inc.


Add the Element of Cognitive Support to Your Products

PLT has a broad range of cognitive health support solutions with strong scientific support. Find out how we can help you put these ingredients to work in your products.